Medine.co.uk

Porcilis Glässer Suspension For Injection For Pigs

Revised: 15 July 2009

AN: 01836/2008

SUMMARY OF PRODUCT CHARACTERISTICS


1. NAME OF THE VETERINARY MEDICINAL PRODUCT


Porcilis Glässer Vet Suspension for injection for pigs (DK-FI-NO)

Porcilis Glässer Suspension for injection for pigs (AT-BE-DE-EL-ES-FR-IE-LU-NL-PT-UK-CY-CZ-SK-SI-HU-PL-EE-LV)

Porsilis Glässer Suspension for injection for pigs (IT)


2. QUALITATIVE AND QUANTITATIVE COMPOSITION


Per dose of 2 ml


Active substance(s):

Inactivated whole bacterial cells of Haemophilus parasuisserotype 5, strain 4800: 0.05 mg total nitrogen, inducing 9.1 Elisa Units*.


Adjuvant:

150 mg dl--tocopheryl acetate


Excipients:

For a full list of excipients, see section 6.1.


3. PHARMACEUTICAL FORM


Suspension for injection

Appearance: aqueous, white or nearly white suspension


4. CLINICAL PARTICULARS


4.1 Target species


Pigs and sows.


4.2 Indications for use, specifying the target species


Pigs:

Active immunisation of pigs to reduce typical lesions of Glässer’s disease caused by Haemophilus parasuis serotype 5.

Onset of immunity: 2 weeks after completion of vaccination.

Duration of immunity: 14 weeks after completion of vaccination.


Sows:

For passive immunisation of the progeny of vaccinated sows and gilts to reduce infection, mortality, clinical signs and typical lesions of Glässer disease caused by Haemophilus parasuis serotype 5 and to reduce clinical signs and mortality caused by Haemophilus parasuis serotype 4.

Onset of immunity: After birth and sufficient uptake of colostrum.

Duration of immunity has been demonstrated at 4 weeks of age against serotype 4 and at 6 weeks of age against serotype 5.


4.3 Contraindications


None.


4.4 Special warnings


None


4.5 Special precautions for use


Special precautions for use in animals


Vaccinate only healthy animals. In the event of anaphylactic reaction consult your veterinarian.


Special precautions to be taken by the person administering the veterinary medicinal product to animals


In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.


4.6 Adverse reactions (frequency and seriousness)


Pigs:

A transient increase in temperature (≤ 2°C) in combination with signs of general discomfort, such as less activity, depression and vomiting may occur on the day of vaccination. The next day the animals are back to normal. Local reactions (painless reddish swellings of 2,5-7,5 cm) may be observed in some pigs until 3 days after vaccination. Systemic anaphylactic reactions may occur in very rare cases (e.g. less than 1 animal in 10,000 animals).


Sows:

A transient increase in temperature may occur (mean 0.9C, with individual animals displaying a temperature increase of above 2°C). A tendency to lie down, reduced feed and water intake and minor signs of illness may be observed 1 to 2 days after vaccination. All animals return to normal within 1 to 3 days after vaccination. Transient local reactions consisting mostly of non-painful swellings with a diameter smaller than 10 cm may be observed. In some cases swelling may be warm, red and painful with a size larger than 10 cm. These local reactions disappear or clearly diminish 14 days after vaccination.


4.7 Use during pregnancy, lactation or lay


Can be used during pregnancy.


4.8 Interaction with other medicinal products and other forms of interaction


No information is available on the compatibility of this vaccine with any other. Therefore the safety and efficacy of this product when used with any other (either when used on the same day or at different times) has not been demonstrated.


4.9 Amounts to be administered and administration route


Allow vaccine to reach ambient temperature. Shake well before use.

Administer 2 ml (one dose) of the vaccine intramuscularly in the neck of the pig.


The vaccine is of benefit when pigs and sows with no or low levels of antibodies against H. parasuis serotype 5 are mixed with animals from or in an environment with higher prevalence of Glässers diseaseor if the piglets from sows with no or low antibodies are reared in such environment.Vaccination of sows with moderate to high levels of antibodies has not been shown to provide additional protection of the offspring. The control of Glässers disease is also dependent on management factors and reduction of stress.

Antibodies against H. parasuis serotype 5 have been shown to be cross-reactive against H. parasuis serotype 4.


Vaccination scheme pigs:

Vaccinate pigs of at least five weeks of age twice with an interval of two weeks.


Vaccination scheme sows:

Vaccinate sows at 6 to 8 weeks before expected time of farrowing twice with an interval of four weeks.


Revaccination scheme sows:

For sows vaccinated during the previous pregnancy, a single revaccination at 4 to 2 weeks before farrowing is recommended.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary


Pigs:

After vaccination with a twofold overdose, reactions are not different from those after the single dose.

Sows:

After vaccination with a twofold overdose, a transient increase in temperature may occur (mean 1.8 C, with a maximum observed temperature of 41.3 C). Other reactions are not different from those after a single dose.


4.11 Withdrawal period(s)


Zero days


5. IMMUNOLOGICAL PROPERTIES


Pharmacotherapeutic group: Inactivated bacterial vaccine.

ATC vet code: QI 09AB07.


The product stimulates the development of active immunity against Haemophilus parasuisserotype 5. Serotype 5 is the most prevalent under the virulent serotypes of H. parasuis.There is some cross protection to the other virulent serotypes, but full cross protection cannot be assured. The product stimulates transfer of passive immunity against Haemophilus parasuisserotype 5 and 4 to the progeny after vaccination of pregnant sows. It contains an aqueous adjuvant.


6. PHARMACEUTICAL PARTICULARS


6.1 List of excipients


phosphate buffer

simethicone

water for injections

polysorbate 80


6.2 Imcompatibilities


Do not mix with any other vaccine or immunological product.


6.3 Shelf life


Shelf-life of the veterinary medicinal product as packaged for sale


PET vials: 2 years

Glass vials: 1 year


Shelf-life after first opening the immediate packaging

Use broached vials immediately.


6.4 Special precautions for storage


Store in a refrigerator (2°C - 8°C)

Do not freeze.

Protect from light.


6.5 Nature and composition of immediate packaging


Vials of PET or Glass type I (Ph. Eur.) containing 20 ml (10 dose presentation), 50 ml (25 dose presentation) or 100 ml (50 dose presentation), closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap.


Porcilis Glässer is presented in cartons containing 1, 6 or 12 vials of 20 ml, 50 ml or 100 ml.

Not all pack sizes may be marketed.


6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused product or waste material should be disposed of in accordance with national requirements.


7. MARKETING AUTHORISATION HOLDER


Intervet International B.V. represented by

Intervet UK Ltd

Walton Manor

Walton

Milton Keynes

MK7 7AJ


8. MARKETING AUTHORISATION NUMBER(S)


Vm06376/4037


9. DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION

13-03-2003 / 13-03-2008.


10. DATE OF REVISION OF THE TEXT


15 July 2009


Prohibition of sale, suply and/or use


Not applicable.


* ELISA units = mean antibody titre (log2 value) in the potency test in mice.